Shares of Sangamo BioSciences Inc. (NASDAQ:SGMO) rose 3.1% during trading on Tuesday . The company traded as high as $4.97 and last traded at $4.95, with a volume of 494,096 shares traded. The stock had previously closed at $4.80.

SGMO has been the subject of a number of recent analyst reports. Janney Montgomery Scott cut shares of Sangamo BioSciences from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $15.00 to $8.00 in a research note on Thursday, August 4th. Jefferies Group reiterated a “buy” rating and issued a $14.00 target price on shares of Sangamo BioSciences in a research note on Thursday, June 9th. Wells Fargo & Co. began coverage on shares of Sangamo BioSciences in a research note on Tuesday, May 3rd. They issued a “buy” rating for the company. Zacks Investment Research cut shares of Sangamo BioSciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 5th. Finally, Wedbush restated an “outperform” rating and set a $30.00 price objective on shares of Sangamo BioSciences in a research note on Friday, May 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $15.58.

The stock’s market capitalization is $346.82 million. The firm’s 50-day moving average is $5.79 and its 200-day moving average is $6.04.

Sangamo BioSciences (NASDAQ:SGMO) last released its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.14. The company had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $5.38 million. The business’s revenue for the quarter was down 56.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.17) EPS. On average, equities research analysts anticipate that Sangamo BioSciences Inc. will post ($1.11) earnings per share for the current year.

An institutional investor recently raised its position in Sangamo BioSciences stock. Royce & Associates LLC boosted its position in Sangamo BioSciences Inc. (NASDAQ:SGMO) by 47.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 312,100 shares of the biopharmaceutical company’s stock after buying an additional 100,000 shares during the period. Royce & Associates LLC owned approximately 0.45% of Sangamo BioSciences worth $2,849,000 at the end of the most recent reporting period.

Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.